Immune checkpoint blockade in cancer therapy
Immune checkpoint blockade in cancer therapy: historical perspective, new opportunities, and prospects for cures
Air date: Wednesday, March 11, 2020, 3:00:00 PM
Category: WALS - Wednesday Afternoon Lectures
Runtime: 01:03:23
Description: NIH Director’s Wednesday Afternoon Lecture Series
James Allison is the Chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, Director of the Parker Institute for Cancer Research, and the Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center. He has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy. He earned the 2018 Nobel Prize in Physiology or Medicine, which he shared with Dr. Tasuku Honjo, "for their discovery of cancer therapy by inhibition of negative immune regulation."
Among Allison's most notable discoveries are the determination of the T cell receptor structure and that CD28 is the major costimulatory molecule that allows full activation of naïve T cells and prevents anergy in T cell clones. His lab resolved a major controversy by demonstrating that CTLA-4 inhibits T-cell activation by opposing CD28-mediated costimulation and that blockade of CTLA-4 could enhance T cell responses, leading to tumor rejection in animal models. This finding paved the wave for the emerging field of immune checkpoint blockade therapy for cancer. Work in his lab led to the development of ipilimumab, an antibody to human CTLA-4 and the first immune checkpoint blockade therapy approved by the FDA. Among many honors, he is a member of the National Academies of Science and Medicine and received the Lasker-DeBakey Clinical Medical Research award in 2015. His current work seeks to improve immune checkpoint blockade therapies currently used by our clinicians and identify new targets to unleash the immune system in order to eradicate cancer.
Author: James P. Allison, Ph.D., Nobel Prize in Physiology or Medicine (2018), MD Anderson Cancer Center, University of Texas
Permanent link: https://videocast.nih.gov/watch=36081
Видео Immune checkpoint blockade in cancer therapy канала NIH VideoCast
Air date: Wednesday, March 11, 2020, 3:00:00 PM
Category: WALS - Wednesday Afternoon Lectures
Runtime: 01:03:23
Description: NIH Director’s Wednesday Afternoon Lecture Series
James Allison is the Chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, Director of the Parker Institute for Cancer Research, and the Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center. He has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy. He earned the 2018 Nobel Prize in Physiology or Medicine, which he shared with Dr. Tasuku Honjo, "for their discovery of cancer therapy by inhibition of negative immune regulation."
Among Allison's most notable discoveries are the determination of the T cell receptor structure and that CD28 is the major costimulatory molecule that allows full activation of naïve T cells and prevents anergy in T cell clones. His lab resolved a major controversy by demonstrating that CTLA-4 inhibits T-cell activation by opposing CD28-mediated costimulation and that blockade of CTLA-4 could enhance T cell responses, leading to tumor rejection in animal models. This finding paved the wave for the emerging field of immune checkpoint blockade therapy for cancer. Work in his lab led to the development of ipilimumab, an antibody to human CTLA-4 and the first immune checkpoint blockade therapy approved by the FDA. Among many honors, he is a member of the National Academies of Science and Medicine and received the Lasker-DeBakey Clinical Medical Research award in 2015. His current work seeks to improve immune checkpoint blockade therapies currently used by our clinicians and identify new targets to unleash the immune system in order to eradicate cancer.
Author: James P. Allison, Ph.D., Nobel Prize in Physiology or Medicine (2018), MD Anderson Cancer Center, University of Texas
Permanent link: https://videocast.nih.gov/watch=36081
Видео Immune checkpoint blockade in cancer therapy канала NIH VideoCast
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![James Allison, PhD - Immune Checkpoint Blockade in Cancer Therapy (2020)](https://i.ytimg.com/vi/hfE9_X05sSo/default.jpg)
![Introduction to Immunotherapy (Immunotherapy Documentary Part I)](https://i.ytimg.com/vi/8Z0Gyv-3NL8/default.jpg)
![Immune Checkpoint Inhibitors](https://i.ytimg.com/vi/GIUu239FWMg/default.jpg)
![TRACO 2019 - Ovarian cancer and Immune checkpoints](https://i.ytimg.com/vi/ansca_kLpfg/default.jpg)
![Cancer Immunotherapy: 2020 Research Update and a Look Ahead with Dr. Padmanee Sharma](https://i.ytimg.com/vi/kyUVQCTj_Uk/default.jpg)
![Modulating Tumor-Associated Macrophage](https://i.ytimg.com/vi/WjxwBEdbHF4/default.jpg)
![Immune checkpoint blockade in cancer therapy](https://i.ytimg.com/vi/0rok3P0-Cfs/default.jpg)
![Coping With Stress - Imaginative Solutions for Stress Relief](https://i.ytimg.com/vi/FOQKMiD5QJI/default.jpg)
![These Viruses Are Forever: Consequences of Retroviral DNA Integration to Aids and Evolution](https://i.ytimg.com/vi/rVi2ok42oSA/default.jpg)
![Targeting Cancer Pathways: Understanding Immune Checkpoints](https://i.ytimg.com/vi/zhnAvTxhZB0/default.jpg)
![WEBINAR: Radiation Therapy for Brain Tumors](https://i.ytimg.com/vi/aSuSLn4CN6g/default.jpg)
![Human Oncogenic Viruses: Nature, Discovery, and Running Around in Circles](https://i.ytimg.com/vi/46-hDz2gupU/default.jpg)
![Immune Checkpoint Inhibitor Associated Renal Disease](https://i.ytimg.com/vi/mqd_4WijfVE/default.jpg)
![Cancer Therapy: By inhibition of Negative Immune Regulation (Robbins Pathology 10 ed update)](https://i.ytimg.com/vi/9NrcLHQUuN0/default.jpg)
![Nobel Lecture: James Allison, Nobel Prize in Physiology or Medicine 2018](https://i.ytimg.com/vi/0kuh7G9CP9Y/default.jpg)
![Emily Levesque Public Lecture: The Weirdest Stars in the Universe](https://i.ytimg.com/vi/YR-l0b2iYy0/default.jpg)
![Immuno-Oncology: A Future Look](https://i.ytimg.com/vi/6mwK3Ylh_VU/default.jpg)
![Molecular Testing for Alterations in DNA Damage Repair Pathway Genes](https://i.ytimg.com/vi/crBAR8uf2LQ/default.jpg)
![TRACO 2017 - Ovarian Cancer in the Genomics Era and Immune checkpoints](https://i.ytimg.com/vi/ryHatZDgnmE/default.jpg)
![New Concepts in Immunotherapy for Solid Tumors](https://i.ytimg.com/vi/iR5X_bLDOX0/default.jpg)